Cassava Sciences Settles SEC Dispute, Focuses on Alzheimer’s Trials
Company Announcements

Cassava Sciences Settles SEC Dispute, Focuses on Alzheimer’s Trials

The latest update is out from Cassava Sciences ( (SAVA) ).

Cassava Sciences has settled with the SEC over allegations of misleading statements related to its Alzheimer’s drug trial, agreeing to a $40 million penalty while not admitting wrongdoing. The settlement, awaiting court approval, also involves two former employees and comes with a permanent injunction against future violations. Cassava has since taken steps to bolster corporate governance and is focusing on ongoing Phase 3 trials, with a hopeful outlook for its drug simufilam’s potential to aid Alzheimer’s patients.

Find detailed analytics on SAVA stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyLargest borrow rate increases among liquid names
TheFlyCassava Sciences put volume heavy and directionally bearish
TheFlyCassava Sciences call volume above normal and directionally bullish
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App